Viewing nowEslatanzin 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

MFDS item code 201707655 · Approved 2017.10.30 · Insurance code 622803050
Treatment of essential hypertension and heart failure, and reduction of the risk of death after myocardial infarction
This medication is used to control blood pressure in patients with essential hypertension to improve health. Additionally, it helps alleviate symptoms of heart failure in patients with intolerance to ACE inhibitors, specifically those categorized as NYHA class II to IV. It has been shown to reduce the risk of death in stable patients with left ventricular dysfunction following myocardial infarction. Thus, this drug is effective in managing hypertension, treating heart failure, and reducing risk post-myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing its dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, the dose is increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension: 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious damage to the fetus and newborn when taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This drug should not be used by individuals who are allergic to this medication or its components, pregnant women or those who may become pregnant, nursing mothers, patients with severe liver impairment, and certain patients with kidney impairment. Elderly patients, patients with hyperkalemia, liver disease, and cardiovascular and kidney disorders should use this drug with caution and closely monitor for signs of hypotension or changes in kidney function. While taking this drug, side effects such as headache, dizziness, cough, diarrhea, and fatigue may occur, and rarely serious adverse reactions such as angioedema, hepatitis, or renal failure may manifest; thus, if unusual symptoms occur, medical consultation should be sought immediately. This drug can cause a sudden drop in blood pressure, so care must be taken to monitor for symptoms of hypotension at the start of treatment or when increasing the dose, and appropriate treatment should be obtained if necessary. Interaction with other medications is possible, so healthcare providers should be informed, especially when used in conjunction with potassium-sparing diuretics, non-steroidal anti-inflammatory drugs, or lithium preparations, and blood pressure, kidney function, and electrolyte levels should be regularly checked. This drug is not recommended for nursing mothers, and it is considered safe to discontinue breastfeeding while on this medication. The safety and efficacy in children and adolescents under 18 years of age have not been established, so its use is not advisable. In case of overdose, severe hypotension or altered consciousness may occur, necessitating immediate emergency response, and dialysis is not effective. Store this drug out of reach of children, and avoid transferring it to other containers as this could adversely affect quality.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air and moisture, and kept in a cool place below 30 degrees Celsius. It is important to avoid direct sunlight, high temperatures, and humidity.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Mothers Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.